Clinical Trial of SP-2577 (Seclidemstat) in Patients With Relapsed or Refractory Ewing or Ewing-related Sarcomas

ClinicalTrials.gov ID: NCT03600649

Public ClinicalTrials.gov record NCT03600649. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 20, 2026, 8:52 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase 1 Trial of the LSD1 Inhibitor Seclidemstat (SP 2577) With and Without Topotecan and Cyclophosphamide in Patients With Relapsed or Refractory Ewing Sarcoma and Select Sarcomas

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Single agent, non-randomized, open label expansion in select sarcoma patients including myxoid liposarcoma and other sarcomas that share similar chromosomal translocations to Ewing sarcoma; AND dose expansion of the combination of seclidemstat with topotecan and cyclophosphamide in patients with Ewing sarcoma

Study identification

NCT ID: NCT03600649
Recruitment status: Not listed
Study type: Interventional
Phase: Phase 1
Lead sponsor: Salarius Pharmaceuticals, LLC; Industry
Enrollment: 50 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range: 12 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jun 4, 2018 (Actual)
Primary completion: Sep 2025 (Estimated)
Completion: Dec 2025 (Estimated)
Last update posted: Nov 21, 2023

2018 – 2025

United States locations

U.S. sites: 16
U.S. states: 12
U.S. cities: 16

Facility	City	State	ZIP	Site status
Children's Hospital Los Angeles	Los Angeles	California	90027	—
Sarcoma Oncology Research Center	Santa Monica	California	90403	—
Mayo Clinic	Jacksonville	Florida	32224	—
Johns Hopkins All Children's Hospital	St. Petersburg	Florida	33701	—
H. Lee Moffitt Cancer Center and Research Institute	Tampa	Florida	33612	—
Dana-Farber Cancer Institute	Boston	Massachusetts	02215	—
Mayo Clinic	Rochester	Minnesota	55905	—
Washington University	St Louis	Missouri	63110	—
Memorial Sloan Kettering Cancer Center	New York	New York	10065	—
Cleveland Clinic Taussig Cancer Institute	Cleveland	Ohio	44195	—
The Research Institute at Nationwide Children's Hospital	Columbus	Ohio	43205	—
Oregon Health Sciences University	Portland	Oregon	97239	—
Fox Chase Cancer Center	Philadelphia	Pennsylvania	19111	—
MD Anderson Cancer Center	Houston	Texas	77030	—
Virginia Cancer Specialists	Fairfax	Virginia	77030	—
University of Washington	Seattle	Washington	98109	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT03600649, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Nov 21, 2023 · Synced Oct 20, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT03600649 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →